Treat dupilumab-induced ocular surface disease aggressively

Aggressive therapies can treat dupilumab-induced ocular surface inflammation and, depending on the severity of the inflammation, can allow a patient to continue use of the dermatologic therapy.
Preservative-free artificial tears, ointments at bedtime, punctal plugs and a short course of topical steroids can treat ocular surface symptoms caused by eczema treatment Dupixent (dupilumab, Regeneron/Sanofi), Ashley Brissette, MD, MSc, FRCSC, told Ocular Surgery News.
When ocular side effects of keratitis and conjunctivitis are severe or persistent, stopping dupilumab may be a consideration.

Full Story →